Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Jan 28;46(1):47-52. doi: 10.11817/j.issn.1672-7347.2021.200004.
A variety of causes can lead to cholestasis, however, cholestasis caused by Graves' disease is usually overlooked clinically. Here we analyze the clinical characteristics of Graves' disease associated cholestasis so as to have a better understanding for the disease.
We retrospectively collected 13 inpatients' data who suffered from the Graves' disease associated cholestasis in the Department of Infectious Disease of Xiangya Hospital from January 2000 to December 2018. The characteristics of the patients' age, gender, liver function, thyroid function, coagulation function, the special cardiac examination, treatment, and follow-up data were analyzed.
Thirteen patients, including 10 males and 3 females with the age range from 33 to 55 (median 43) years old presented cholestasis, pruritus, and hypermetabolic symptoms. The levels of total bilirubin (TBIL), direct bilirubin (DBIL), glutamic-pyruvic transferase, glutamic-oxaloacetic transferase, alkaline phosphosphatase, and gamma glutamyl transpeptidase were 170.4-976.7 (median 388.8) µmol/L, 93.2-418.1 (median 199.2) µmol/L, 25.1-182.1 (median 106.4) U/L, 38.2-265.7 (median 59.7) U/L, 105.3-332.0 (median 184.5) U/L, and 20.7-345.1 (median 47.6) U/L, respectively. The levels of free triiodothyronine (FT), free thyroxine (FT), and thyrotrophin receptor antibody were 4.1-50.0 (median 21.6) pmol/L, 30.4-100.0 (median 87.9) pmol/L, and 4.2-40 (median 19.8) U/mL, respectively. All patients' coagulation function, heart size, and ejection fraction (EF) value were normal. After anti-thyroid treatment, the levels of FT, FT, and TBIL decreased. Through telephone interview, we were able to know that after 6 months of anti-thyroid treatment, the level of FT, FT, and TBIL in these patients returned to normal, and the itch symptom disappeared completely.
Graves' disease can cause cholestasis, with the low incidence. The symptoms of cholestasis can be improved or even eradicated with the cure of the Graves' disease. The cholestasis may be idiopathic. For patients with cholestasis and hyperthyroidism, Graves' disease should be considered for differential diagnosis.
多种原因可导致胆汁淤积,但临床上常忽略由 Graves 病引起的胆汁淤积。本研究旨在分析 Graves 病相关胆汁淤积的临床特征,以加深对该病的认识。
回顾性收集 2000 年 1 月至 2018 年 12 月在湘雅医院感染科住院的 13 例 Graves 病相关胆汁淤积患者的临床资料,分析其年龄、性别、肝功能、甲状腺功能、凝血功能、特殊心脏检查、治疗及随访资料等特点。
13 例患者中,男 10 例,女 3 例,年龄 3355 岁,中位年龄 43 岁,均有胆汁淤积、瘙痒和高代谢症状。总胆红素(TBIL)、直接胆红素(DBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(γ-GT)水平分别为 170.4976.7(中位 388.8)μmol/L、93.2418.1(中位 199.2)μmol/L、25.1182.1(中位 106.4)U/L、38.2265.7(中位 59.7)U/L、105.3332.0(中位 184.5)U/L 和 20.7345.1(中位 47.6)U/L,游离三碘甲状腺原氨酸(FT₃)、游离甲状腺素(FT₄)、促甲状腺素受体抗体(TRAb)水平分别为 4.150.0(中位 21.6)pmol/L、30.4100.0(中位 87.9)pmol/L 和 4.240(中位 19.8)U/ml。所有患者凝血功能、心脏大小、射血分数(EF)值均正常。经抗甲状腺治疗后,FT₃、FT₄、TBIL 水平降低。通过电话随访,我们了解到这些患者在抗甲状腺治疗 6 个月后,FT₃、FT₄、TBIL 水平恢复正常,瘙痒症状完全消失。
Graves 病可引起胆汁淤积,发病率较低。Graves 病治愈后,胆汁淤积的症状可改善甚至消除。胆汁淤积可能是特发性的。对于有胆汁淤积和甲状腺功能亢进的患者,应考虑 Graves 病的鉴别诊断。